The Life Sciences team advised Entrada Therapeutics, Inc. (Nasdaq: TRDA) on its global collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to focus on discovering and developing intracellular Endosomal Escape Vehicle (EEV") therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development.
Under the terms of the agreement, Entrada will receive an upfront payment of $224 million, as well as an equity investment of $26 million. Entrada is eligible to receive up to $485 million for the successful achievement of certain research, development, regulatory and commercial milestones, and tiered royalties on future net sales for any products that may result from this collaboration agreement.
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, EEV" therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.
The Goodwin team was led by Shane Albright, Sarah Ashfaq and Kingsley Taft, and included Christopher Zhong, Katerina Stavrianidis, Brittany Morreale, Alexander Singer, Li Chang, Dan Karelitz, Arman Oruc, Paul Jin with invaluable assistance from Jim Matarese.
For more details, read the press release and articles in Endpoints News, Fierce Biotech and MarketWatch.